These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 31842644)
21. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P]. Liu Y; Ke XY; Wang J; Wang YF; Dong F; Tian L; Wan W; Jing HM Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):802-806. PubMed ID: 28641639 [TBL] [Abstract][Full Text] [Related]
22. Prognostic value and efficacy evaluation of novel drugs for cytogenetic aberrations in multiple myeloma: a meta-analysis. Yu W; Li J; Chen L Int J Clin Exp Med; 2014; 7(11):4051-62. PubMed ID: 25550914 [TBL] [Abstract][Full Text] [Related]
23. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients]. Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352 [No Abstract] [Full Text] [Related]
24. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China. Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918 [TBL] [Abstract][Full Text] [Related]
25. Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study. Chen H; Zhou N; Shi H; Yu W; Wu L; Zhou F Hematology; 2023 Dec; 28(1):2177979. PubMed ID: 36794720 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of daratumumab in newly diagnosed multiple myeloma patients with 1q21 gain. Iriuchishima H; Saito A; Mihara M; Terasaki Y; Matsumoto A; Isoda A; Furukawa Y; Matsumoto M Int J Hematol; 2024 Jul; 120(1):71-79. PubMed ID: 38551778 [TBL] [Abstract][Full Text] [Related]
27. The paradoxical prognostic role of 1q21 Gain/Amplification in multiple myeloma: every coin has two sides. Xu J; Xu T; Yang Y; Wang W; Li J; Ren Y; Gu S; Chen C; Wei Z; Zhuang J; Wang Z; Ji L; Cheng L; Wang W; Cheng Z; Ke Y; Yuan L; Liu P Leuk Lymphoma; 2020 Oct; 61(10):2351-2364. PubMed ID: 32519901 [TBL] [Abstract][Full Text] [Related]
28. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis. Wang YT; Bao L; Chu B; Chen XH; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH J Clin Lab Anal; 2022 Jul; 36(7):e24375. PubMed ID: 35353920 [TBL] [Abstract][Full Text] [Related]
29. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects. Sergentanis TN; Kastritis E; Terpos E; Dimopoulos MA; Psaltopoulou T Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):335-40. PubMed ID: 27101987 [TBL] [Abstract][Full Text] [Related]
30. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. Mohan M; Gong Z; Ashby TC; Al Hadidi S; Thanendrarajan S; Schinke C; Alapat D; Shaughnessy JD; Zhan F; van Rhee F; Sawyer JR; Tian E; Zangari M Cancer; 2023 Aug; 129(16):2491-2498. PubMed ID: 37282609 [TBL] [Abstract][Full Text] [Related]
31. ARNT/HIF-1β links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma. Wu C; Yang T; Liu Y; Lu Y; Yang Y; Liu X; Liu X; Ye L; Sun Y; Wang X; Li Q; Yang P; Yu X; Gao S; Kumar S; Jin F; Dai Y; Li W Cancer Med; 2018 Aug; 7(8):3899-3911. PubMed ID: 29926531 [TBL] [Abstract][Full Text] [Related]
32. The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population. Yu W; Guo R; Qu X; Qiu H; Li J; Zhang R; Chen L Onco Targets Ther; 2016; 9():295-302. PubMed ID: 26834489 [TBL] [Abstract][Full Text] [Related]
33. Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment. Minguela A; Vasco-Mogorrón MA; Campillo JA; Cabañas V; Remigia MJ; Berenguer M; García-Garay MC; Blanquer M; Cava C; Galian JA; Gimeno L; Soto-Ramírez MF; Martínez-Hernández MD; de la Rubia J; Teruel AI; Muro M; Periago A Am J Cancer Res; 2021; 11(9):4438-4454. PubMed ID: 34659897 [TBL] [Abstract][Full Text] [Related]
34. [Influence of Chromosome Abnormality on Therapeutic Efficacy and Prognosis of Newly Diagnosed Multiple Myeloma Treated with Bortezomib]. Sun C; Wang J; Guo HF; Zhou X; Shen YF Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):142-146. PubMed ID: 28245391 [TBL] [Abstract][Full Text] [Related]
35. The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma. Jin Y; Yu X; Du J; Li H; Tang W; Jia C; Zan Y; Chen M; Zhang Y; Yu M; Rong W; Zhou D; Zhuang J Ann Hematol; 2021 May; 100(5):1251-1260. PubMed ID: 33686491 [TBL] [Abstract][Full Text] [Related]
36. Genomic stratification of multiple myeloma treated with novel agents. Jiang A; Reece D; Chang H Leuk Lymphoma; 2012 Feb; 53(2):202-7. PubMed ID: 21823830 [TBL] [Abstract][Full Text] [Related]
37. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains. Chang H; Trieu Y; Qi X; Jiang NN; Xu W; Reece D Leuk Res; 2011 Jan; 35(1):95-8. PubMed ID: 20537706 [TBL] [Abstract][Full Text] [Related]